C3D Patented Solution
to Make Cancer Irrelevant
Chemosen3D proprietary magnetic 3D-based platform tests anti-cancer agents ex vivo to determine reactive therapies on a per patient basis, avoiding the cost and risk to individuals of receiving ineffective drug regimens. ChemoSen3D’s functional 3D assay is poised to be part of pre-screening protocols, along with molecular testing, for personalized treatment decisions.
Our approach utilizes magnetic 3D bioprinting to create patient-derived spheroid for chemo-response testing which maintains tissue heterogeneity: a critical factor for drugresponse determination in physiologically relevant models that will accelerate precision medicine profiling of cancer.
PROBLEM
INEFFECTIVE AND TOXIC CANCER TREATMENTS
Anti-cancer drugs have a global impact on the body
INEFFECTIVE CANCER TREATMENTS
Cancer can be a death sentence to patients, especially for lung, pancreatic, and liver cancer and many types of rare cancers.
TREATMENT SIDE EFFECTS
Life saving treatments have global impacts to the body resulting in poor quality of life and/or inability to tolerate additional treatments.
FINANCIAL STRESS
Costs associated with treatment can be overwhelming.
RARE AND RECURRING CANCERS
Rare cancers have limited treatment options and can represent 20% of cases in some locations.
REDUCED LIFE SPAN
Ineffective and toxic treatments often reduce a patient’s life span.
LIFE AND FAMILY IMPACT
Cancer changes the life of the patient and impacts the caretakers as well.
SolUTION
TREATMENT SIDE EFFECTS
Selecting the most effective compound the first time enables fewer rounds of treatment thereby mitigating toxic side effects.
TREATMENT SIDE EFFECTS
Selecting the most effective compound the first time enables less rounds of treatment thereby mitigating toxic side effects.
FINANCIAL PREDICTIBILITY
Fewer treatments reduces time in the hospital as well as long term costs.
HOPE FOR RARE & RECURRING CANCERS
Rare cancers have fewer treatment options. Targeted treatment recommendations based on patient tumor cells are the key to a better prognosis.
INCREASED LIFE SPAN
Receiving proper treatment the first time can be the difference that leads to a longer life.
IMPACT OF KNOWLEDGE
You will have confidence that you are using the best information available for determining the optimal treatment plan.
WHY CHEMOSEN3D?
Magnetic 3D Bioprinting
Validated, Scalable, Differentiated 3D Cell Culture: Enabling robust research and therapeutic applications.
Proprietary Magnetic 3D Bioprinting: Rapid, efficient cell manipulation for faster results.
Minimal Sample Requirements: Maximizing research value from limited and precious samples.
Data-Rich for creating AI models: Empowering advanced drug development through machine learning and other AI tools
Personalized Guidance
Take Control of Your Treatment: Partner with us to create personalized plan for optimal outcomes.
Increase Your Odds of Success: Benefit from a tailored treatment approach designed specifically for you.
Less Treatment, More Living: Minimize treatment rounds to focus on meaningful moments.
Your Health, Your Priority: Prioritize your well-being for the best possible health outcomes.
Improve Quality of Life: Experience improved well-being and comfort during your journey.
More Than Hope
Beyond Limited Options: We understand that standard treatments may not always be effective for recurring and rare cancers. Our approach goes beyond the limitations of generalized guidelines.
Genetics Is Not Enough: While genetic profiling can be helpful for some patients, it doesn’t provide the full picture. We offer personalized chemosensitivity screening to identify the most effective treatments for you.
Empowering Physicians, Empowering You: Chemosensitivity screening gives your doctor the insights they need to make informed decisions about your treatment, leading to better outcomes.
Your Unique Biology, Your Unique Treatment: We believe that every cancer is different. Our personalized approach ensures that your treatment is tailored to your specific needs and biology.
Data-Driven Decisions: We use cutting-edge technology to analyze your cancer cells and identify the most promising treatment options, maximizing your chances of success.
Phenotypical Meets Genomics
Beyond Genetics: While genomic profiling offers valuable insights, it doesn’t always translate to actionable treatment decisions. Phenotypical screening bridges that gap.
Actionable Insights: Phenotypical screening directly assesses how your unique cancer cells respond to different treatments, giving your doctor clear guidance for personalized therapy.
Targeting Your Tumor’s Behavior: Instead of focusing solely on genetic mutations, we analyze how your cancer cells behave and respond to various drugs, identifying the most effective options.
Precision Medicine in Action: This approach allows us to tailor your treatment to your tumor’s specific vulnerabilities, increasing the likelihood of success.
From Theory to Treatment: We translate complex genomic information into practical, personalized treatment strategies that directly target your cancer cells.”
C3D TECHNOLOGY – IP PROTECTED
FUNCTIONAL CELL-BASED TESTING
PATENTED APPROACH TO RAPID SPHEROID FORMATION
Our patented system provides a high reliability, low cost, miniaturized approach that can be fully automated and eventually used for Point-of-Care testing
Personalized Data Driven Approach to Treatment
The Right Tools.
The Right Solution.
ChemoSen3D’s functional 3D assay is poised to be part of pre-screening protocols, along with molecular testing, for personalized treatment decisions.
Investors
We will soon be opening our Series A Round for new investors interested in advancing our proprietary magnetic 3D technology into the oncology space.
Clinicians
Are you a clinician that sees potential for your patients?
We want to help you.
RESEARCHERS
Cell line or Primary cells that you would like to see in 3D? We can help.
about us
ChemoSen3D grew out of Nano3D Biosciences (n3D) which was a State of Texas C-Corporation founded in 2008 to commercialize products and services utilizing the Bio-Assembler™ technology, n3D founders were Glauco R. Souza (U.T. MD Anderson Cancer Center), Thomas Killian (Rice University) and Robert Raphael (Rice University), who created the technology, and David Lee, who provided business leadership.
STRATEGIC PARTNERSHIPS
Selected Publications
| Year | Author | Title | Link |
|---|---|---|---|
|
2018 |
Eckhardt, B.L. et al. |
Clinically Relevant Inflammatory Breast Cancer Patient-Derived Xenograft–Derived Ex Vivo Model for Evaluation of Tumor-Specific Therapies. |
|
|
2017 |
Hou, S. et al. |
Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening. |
|
|
2017 |
Desai, P. K., Tseng,
H. & Souza, G. R. |
Assembly of Hepatocyte Spheroids Using Magnetic 3D Cell Culture for CYP450 Inhibition/Induction. |
|
|
2017 |
Souza, G. R. et al. |
Magnetically Bioprinted Human Myometrial 3D Cell Rings as a Model for Uterine Contractility. |
|
|
2017 |
Hogan, M. et al. |
Assembly of a Functional 3D Primary Cardiac Construct Using Magnetic Levitation. |
|
|
2014 |
Jaganathan, H. et al. |
Three-Dimensional in Vitro Co-Culture Model
of Breast Tumor Using Magnetic Levitation. |
|
|
2013 |
Timm, D. M. et al. |
A High-Throughput Three-Dimensional Cell Migration Assay for Toxicity Screening with Mobile Device-Based Macroscopic Image Analysis. |
|
|
2010 |
Souza, G. R. et al. |
Three-Dimensional Tissue Culture Based
on Magnetic Cell Levitation. |
|
News
Blog Post Title
What goes into a blog post? Helpful, industry-specific content that: 1) gives readers a useful takeaway, and 2) shows you’re an industry expert. Use your
